A Study for Assessing the Efficacy and Safety ParActin ® in Individuals With Upper Respiratory Tract Infections

Conditions: Upper Respiratory Tract Infections Interventions: Dietary Supplement: ParActin ®: 300 mg + MCC: 100 mg (± 10%) per Capsule; Dietary Supplement: MCC: 400 mg (± 10%) per Capsule Sponsors: Vedic Lifesciences Pvt. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials